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Summary
Numerous T cell subpopulations have now been
claimed to exhibit regulatory activity. Shevach dis-
cusses the current understanding of the different sub-
sets of T regulatory cells and provides a perspective
on the current areas of uncertainly and controversy
in the field.
Introduction
The resurgence of interest in regulatory or suppressor
T cells can be compared to the development of the ice
cream industry in the United States. Howard D. Johnson
was a struggling businessman in the 1920s when he in-
vented a high-butterfat vanilla ice cream and started
a chain of ice cream shops in Massachusetts. His ice
cream rapidly became very popular and he increased
his repertoire from a single flavor to 28 flavors. Suppres-
sor T cells, or as they are now more commonly called, T
regulatory (Treg) cells, were rediscovered in the mid-
1990s by Shimon Sakaguchi (Sakaguchi et al., 1995),
who was the first to demonstrate that a minor population
of CD4+ T cells that coexpressed the CD25 antigen func-
tioned as Treg cells in adult mice. Interest in Treg cells
has exploded over the past 10 years, and numerous
other T cell populations have now been claimed to ex-
hibit regulatory activity. Although we have probably
not yet reached 28 different ‘‘flavors’’ of Treg cells, we
are rapidly approaching that number (Figure 1). I will at-
tempt to summarize our current understanding of the
different types of Treg in both animals and man and to
emphasize the current areas of uncertainly and contro-
versy in the field.
Treg Cells in Mice and Men
The importance of CD4+CD25+ T cells in immune regula-
tion was evident from the initial demonstration that the
depletion of this subset (w10%) from a population of
CD4+ T cells from a normal adult mouse resulted in the
development of a spectrum of autoimmune diseases
when the remaining CD4+CD252 T cells were transferred
to immunoincompetent recipients. The subsequent
demonstration that CD4+CD25+ T cells also manifest
regulatory activity in vitro in a simple and highly repro-
ducible assay (Thornton and Shevach, 1998) formed
the foundation of the resurgence of interest in T cell-
mediated immunoregulation. Human CD4+CD25+ T cells
with functional properties very similar to those of mouse
CD4+CD25+ T cells were subsequently identified by
multiple groups (Shevach, 2001). Any doubts about the
importance of this subset of Treg cells were erased by
*Correspondence: eshevach@niaid.nih.govthe observations that the Foxp3 transcription factor is
selectively expressed in CD4+CD25+ T cells, that it is
required for their development, and that the lethal auto-
immune syndrome that develops in scurfy mice and in
humans with the IPEX (immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked) syndrome is sec-
ondary to a mutation in Foxp3 with a resultant deficiency
in Treg cells (Hori et al., 2003).
The development of Foxp3 monoclonal antibodies
(mAb) that are capable of detecting their target intracel-
lularly by flow cytometry and the development of knockin
mouse strains (Fontenot et al., 2005) where Foxp3 is
coexpressed with a fluorescent label have greatly en-
hanced our ability to define and characterize this Treg
cell subset. In the mouse, there is an excellent correlation
between the expression of Foxp3 and CD25, but a minor
population (10%) of Foxp3+ cells is CD252; conversely,
about 10% of CD25+ T cells are Foxp32 and likely repre-
sent activated effector cells. In humans, the situation
is considerably more complex. Almost all CD4+CD25hi
cells are Foxp3+, whereas a variable percentage of
CD25int cells express lower, but substantial, amounts
of Foxp3. CD4+CD252 cells are uniformly Foxp32. Al-
though flow-cytometric isolation of the cells expressing
the highest amounts of CD25 does allow one to obtain
an almost pure population of human Treg cells, it should
be pointed out that a substantial subset of Foxp3+ cells
will also be lost (the CD25intFoxp3+ cells).
The other important difference between the regula-
tion of Foxp3 expression in mouse and humans is that
Foxp3 expression is readily induced in a majority of both
human CD4+CD252Foxp32 and CD8+CD252Foxp32
T cells by activation via the T cell receptor (TCR),
whereas Foxp3 expression is not induced in mouse
CD252 T cells under similar activating conditions. The
expression of Foxp3 after TCR stimulation of human
CD252 T cells can approach that of the resting
CD4+CD25+Foxp3+ population. However, the induced
Foxp3+ population is neither anergic nor suppressive
in vitro (Gavin et al., 2006), and the expression of Foxp3
appears to be transient, declining to baseline amounts
with prolonged culture. In many respects, the expres-
sion of Foxp3 after activation of human T cells resem-
bles that of CD25—rapid induction and decline. In any
case, one must question whether Foxp3 expression
is an absolute marker of T regulatory cells in humans.
More importantly, one must certainly raise the possibil-
ity that some of the Foxp3+ cells isolated from healthy in-
dividuals or from patients with autoimmune and inflam-
matory diseases represent activated T effector cells.
Appropriate caution should therefore be used in the
evaluation of claims of purported defects of T regulatory
function in disease even when the studies were per-
formed with cells that were CD25+Foxp3+.
‘‘Adaptive’’ or ‘‘Induced’’ Treg Cells
CD4+CD25+Foxp3+ T cells develop in the thymus, and
many investigators have termed these cells ‘‘natural’’
Treg (nTreg) cells in contrast to Treg cells that develop
in peripheral lymphoid tissues, which are frequently
Foxp32 and have been termed ‘‘adaptive’’ or ‘‘induced’’
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196Figure 1. Multiple Flavors of T Regulatory Cells
Several different types of T regulatory cells have been described in the literature. In addition to the ‘‘classic’’ CD4+Foxp3+ thymic-derived T reg-
ulatory cells, a similar population can be induced extrathymically in the presence of TGF-b or other stimuli. CD8+ T regulatory cells have been
poorly characterized. It is not clear how the multiple types are related.Treg cells. Several studies have raised the possibility
that CD4+Foxp3+ cells might also be generated in pe-
ripheral lymphoid tissues from naive CD4+Foxp32 pro-
genitors. Two major factors appear to be involved in
the induction of Foxp3 expression in the periphery—
the cytokine TGF-b and the mode of antigen presenta-
tion. A role for TGF-b in the induction of Treg cells was
first described by Horwitz and colleagues (Yamagiwa
et al., 2001), who demonstrated that TGF-b can induce
naive human CD4+ T cells to develop powerful con-
tact-dependent suppressor activity that is mediated by
TGF-b or IL-10. Other studies (Chen et al., 2003; Fantini
et al., 2004) demonstrated that mouse CD4+CD252
T cells could be converted to CD4+CD25+Foxp3+ T reg-
ulatory cells by stimulation via the TCR in the presence
of TGF-b. The TGF-b-converted CD4+ T cells exhibited
cell-contact-dependent suppressor activity in vitro when
cocultured with normal CD4+ T cells. In addition, antigen-
specific TGF-b-converted cells could inhibit antigen-
driven CD4+ T cell expansion in vivo. Fantini et al. (2004)
also postulated a positive autoregulatory loop in which
Smad 7, a transcription factor that is normally induced
by TGF-b and limits TGF-b signaling, is downregulated
by Foxp3. Foxp3 downregulation of Smad7 then renders
CD252 T cells highly susceptible to the further inductive
effects of TGF-b signaling via Smad3 and Smad4.
Although these studies strongly suggested that costi-
mulation of T cell activation in the presence of TGF-bmay
induce the expression of Foxp3 and regulatory activity, it
was unclear at the time these studies were performed
what percentage of the CD252 T cells were actually con-
verted. The possibility remained that TGF-b was not
inducing Foxp3 expression, but was facilitating the se-
lection of the minor population of CD252Foxp3+ cells
that were present in the starting populations. More re-
cent studies analyzing the expression of Foxp3 on the
single-cell level by intracellular staining have, in fact,
confirmed these initial studies and indicated that 50%–
100% of CD252Foxp32 cells can be induced to express
Foxp3 by costimulation in the presence of TGF-b (Bettelli
et al., 2006). Some of these studies have been performed
with CD4+ T cells from TCR transgenic mice on a RAG-deficient background that are as Foxp32 as a starting
population. Again, there appears to be a difference
between murine and human T cells. Whereas the TGF-
b-induced murine Foxp3+ T cells manifest suppressor
activity both in vitro and in vivo, it has yet to be shown
that the TGF-b-induced human T cells behave in similar
fashion. As noted above, Foxp3 expression in human
T cells does not uniformly correlate with suppressor ac-
tivity, and in our hands (D. Tran and E.M.S., unpublished
data), TGF-b-induced Foxp3+ human T cells are neither
anergic nor suppressive. This result may indicate that
Foxp3 is necessary, but not sufficient, for human Treg
function. Other explanations including the stimulatory
conditions, the stability of Foxp3 expression, and the
absolute amount of Foxp3 induced may also account
for the species difference.
The second major factor that appears to induce Foxp3
expression in Foxp32 peripheral T cells is the mode
of antigen presentation. When peptide-specific T cells
from TCR transgenic mice on RAG-deficient background
are stimulated in vivo for 2 weeks by the continuous de-
livery of low doses of antigen via a mini-osmotic pump,
the antigen-specific cells expressed Foxp3 and could
suppress proliferation and cytokine production in vivo
(Apostolou and von Boehmer, 2004). Similar results
were observed when animals were primed with minute
amounts of peptide coupled to the mAb DEC205 that
targeted the antigen to dendritic cells (DCs) (Kretschmer
et al., 2005). Exposure of TCR transgenic T cells to their
target antigen expressed endogenously in soluble form
also resulted in the induction of Foxp3 expression and
Treg cell activity (Knoechel et al., 2005). It is unclear
whether TGF-b plays a costimulatory role in these in
vivo models, although peptide-specific T cells from
mice expressing a dominant-negative form of the TGF-
b-receptor II developed many fewer Foxp3+ T cells
in vivo than T cells from wild-type mice when primed
with peptide-DEC205 complexes. Taken together, these
studies suggest that antigen presentation under certain
conditions, presumably in the absence of DC activation,
results in the generation of Foxp3+ suppressor rather
than effector T cells.
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physiologic relevance of the peripheral induction of
Foxp3+ Treg cells. TGF-b is a ubiquitously expressed
cytokine produced by many cell types whose expres-
sion is increased at local sites of inflammation. Although
some studies (Cobbold et al., 2004; Ochando, et al.,
2006) suggest that certain protocols used for the induc-
tion of transplantation tolerance in vivo mediate their ef-
fects by the TGF-b-dependent induction of Foxp3+ Treg
cells, numerous questions regarding the induction of
Foxp3+ Treg cells remain to be addressed: What per-
centage of the CD4+CD25+Foxp3+ T cells present in
the periphery of a normal adult is thymus-derived, and
what percentage is induced in the periphery? If TGF-
b is constantly promoting the induction of Treg cells,
why does the absolute number of Treg cells remain rel-
atively constant throughout the lifetime of an animal? Is
there a parallel death pathway for certain subsets (thy-
mic or peripheral) of Foxp3+ Treg cells? Are the effects
of TGF-b continuously antagonized in vivo by the pres-
ence of IL-6 in the periphery, resulting in the induction
of proinflammatory rather than anti-inflammatory T cells
(Bettelli et al., 2006)? How is the delicate balance be-
tween TGF-b induction of Foxp3+ Treg cells and the
combined effects of TGFb and IL-6 in the induction of
IL-17-producing T cells regulated? Are human TGF-b-
induced Foxp3+ cells fully competent Treg cells? If not,
what component is missing? Lastly, can the limited an-
tigen dose and nonactivated DC strategy for the induc-
tion of Treg in animal studies be developed for use as
a vaccine to generate organ-specific Treg for the treat-
ment of autoimmune disease?
Identification and Isolation of Foxp3+ Treg
One problem that has plagued the Treg cell field is the
identification of cell-surface markers that can be used
to reproducibly and reliably isolate pure populations of
Treg cells. Homogenous populations of Treg cells are
needed for functional studies and for in vitro expansion
for potential therapeutic purposes. More importantly, for
studies of abnormalities in Treg cell function in disease,
methods are needed to obtain not only pure Treg cells,
but also a population that is representative of the entire
population of Treg cells in vivo. Put simply, a population
of CD4+CD25+ T cells that are 100% Foxp3+ might be
quite suitable for many studies. However, if CD25 ex-
pression is downmodulated in disease or during the
course of an inflammatory response (Fontenot et al.,
2005), an analysis of the frequency and function of
only the CD4+CD25+ population might be misleading.
The expression of Foxp3 protein intracellularly as de-
tected by antibodies or in animals that express a Foxp3-
GFP fusion protein is now accepted as the ‘‘gold stan-
dard’’ for defining either thymic-derived Treg cells or
Treg cells that might be generated in the periphery.
The availability of mice that express a Foxp3-GFP fusion
protein allows one to clearly define and isolate nTreg.
These mice are being rapidly bred onto multiple back-
grounds to facilitate analysis of nTreg function in dis-
ease. It would also be advantageous to have a mouse
that expressed a cell-surface marker (e.g, human CD2)
under the control of the Foxp3 promoter so magnetic
bead-separation technologies could be used. Other
markers that have been proposed as being useful for
the identification of Treg have proven to be less useful.Many of these identify activation antigens, including
CTLA-4, GITR, and other members of the TNF-receptor
superfamily, that are also expressed by activated effec-
tor T cells. Some, including neuropilin, CD38, and CD5
(Knoechel et al., 2006), appear to be shared with
Foxp32 anergic T cells that do not exert suppressive
functions.
Identification and isolation of human Treg cells con-
tinues to be a dilemma, because one must rely on ex-
pression of cell-surface antigens. Although CD25 ex-
pression has been used to identify human Treg cells,
CD25 is expressed on a high percentage of human T
cells, and only the highest CD25 expressors (w2% of
CD4+ T cells) have been claimed to exert significant sup-
pressive effects (Baecher-Allan et al., 2001). However,
a higher percentage of human CD4+ T cells express
Foxp3, but lower amounts of CD25 (Liu et al., 2006). It
was also proposed that almost all of the human
Foxp3+ T cells can be identified as expressing low IL-7
receptor (CD127) and that CD127lo expression can be
used to isolate human Treg cells. There is, however, a
major theoretical problem with the choice of CD127lo
as a Treg cell marker. CD25 is not ideal because it is
expressed on some activated effector cells. Similarly,
expression of CD127 is also downregulated early in the
course of T cell activation, so the CD127lo phenotype
is also unlikely to be Treg cell specific during an ongoing
immune or inflammatory response. In addition, only
about 40% of the CD127lo population is Foxp3+, and
even purified CD4+CD127loCD25+ cells were only
85%–90% Foxp3+. Thus, the utility of using the differen-
tial expression of CD127 for the isolation of human Treg
cells requires further study.
Lastly, one must consider the possibility of subpopu-
lations of Foxp3+ Treg cell with different functional prop-
erties. The most interesting marker of a potential Treg
cell subpopulation is the integrin (aEb7, CD103) that is
expressed on approximately 25% of mouse Treg cells,
and that controls the adherence of conventional T cells
to epithelium in the gut by binding to E cadherin. The
subset of CD25+CD103+ T cells appears to exert more
potent suppressive effects in vitro and to be expressed
on Treg cells that circulate preferentially to inflammatory
sites (Huehn et al., 2004). Certain chemokine receptors
may also be preferentially expressed on Treg subpopu-
lations, but more study is needed to determine whether
their differential expression defines functionally distinct
populations.
Antigen-Induced CD4+ IL-10-Producing Treg Cells
One of the first procedures used for the induction of Treg
cells in vivo was administration of antigen by the oral
route. Oral administration of antigen can result in dele-
tion of antigen-specific T cells after high-dose antigen
delivery or the induction of Treg cells at low concentra-
tions of antigen. The selective induction of Treg cells via
the oral route is thought to be secondary to poorly char-
acterized properties of gut-resident antigen-presenting
cells (APCs). In some studies, clones derived from
mice that have been orally tolerized with low antigen
dose primarily produced TGF-b, and these cells were
termed Th3 cells. Progress in the further characteriza-
tion of Treg cells induced by oral tolerance has been
slow, and Treg cells that exclusively produce TGF-b
have not been frequently observed in other models.
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oral-tolerance studies is that the milieu in which T cells
are primed plays an important role in determining
whether effector cells or suppressor cells are generated.
One systematic approach to the analysis of the prim-
ing milieu was to culture murine or human CD4+ T cells
with antigen or alloantigen in the presence of exogenous
IL-10 (O’Garra and Vieira, 2004). Clones derived from
this protocol produced large amounts of IL-10, some
TGF-b, IFN-g, and IL-5, but no IL-2 or IL-4. CD4+ T cells
generated in this manner have been termed T regulatory
1 (Tr1) cells. IL-10-producing Treg cells can also be gen-
erated in vitro by culture in a combination of vitamin D,
dexamethasone, and cognate antigen. Homogeneous
populations of Tr1 cells do not express Foxp3, can arise
in the absence of nTreg cells, but inhibit T cell prolifera-
tion with comparable efficiency to nTreg cells. In con-
trast to nTreg cells whose antigenic specificity is fre-
quently unknown, Tr1 cells are by definition antigen
specific. However, in some models, Foxp3+ nTreg cells
have also been shown to be both antigen specific and
IL-10 producers (Suffia et al., 2006), blurring the distinc-
tion between the Treg cell subsets. Although most of the
suppressive activity of Tr1 cells is secondary to the
production of IL-10 and perhaps TGF-b, some IL-10-
producing Tr1 cells suppress the proliferation of naive
CD4+ T cells in vitro by an IL-10-independent, cell-con-
tact-dependent mechanism (Vieira et al., 2004). Here
again, the distinction between the various flavors of
Treg cells is not at all clear.
The capacity of IL-10 to induce Tr1 cells in vitro has a
direct in vivo correlate in the immune response to certain
infectious agents. Pathogen-specific Tr1 cells can be
generated in vivo during the course of bacterial, viral,
fungal, or parasitic infections. The major purpose of
these cells is to control inflammation and collateral tis-
sue damage. Chronic infectious states may result if this
mechanism is subverted by the pathogen. It has been
proposed that a unique cytokine environment with en-
hanced IL-10 production and decreased IL-12 produc-
tion is created during the course of infection (Mills,
2004). For example, the filamentous hemagglutinin anti-
gen derived fromBordetella pertussis induces IL-10 pro-
duction and inhibits IL-12 production by DCs and macro-
phages. These pathogen-derived products may also
modulate costimulatory molecule expression by DCs,
thereby creating a favorable environment for induction
of Tr1 cells rather than Th1-Th2 effector cells. Pathogen
products may also directly interact with their cellular
receptors on T cells, resulting in the generation of Tr1
populations. For example, IL-10-producing Tr1 cells
have been generated in vitro by antibody-mediated col-
igation of CD46 and CD3 on human T cells, and this pro-
cess may mimic ligation of CD46 by a pathogen-derived
ligand (Kemper et al., 2003).
CD8+ T Regulatory Cells
Although the most prominent suppressor T cell popula-
tions of the 1970s and 1980s were CD8+ T cells, there
has been a reluctance to re-explore the role of CD8+
T cells as Treg cells. More importantly, because
CD4+CD25+Foxp3+ T cells are potent suppressors of
the activation of CD8+ T cells (Piccirillo and Shevach,
2001), there has been no need for a unique CD8-specific
regulatory cell. Nevertheless, there have been a numberof reports of CD8+ T cells with regulatory functions.
CD8+ Treg cells indeed come in many ‘‘flavors,’’ and
most of them have been characterized in a limited
number of experimental models by only one or two
laboratories.
One class of CD8+ Treg cells appears to recognize
peptides derived from cell-surface antigens in associa-
tion with classical or nonclassical MHC class I antigens.
CD8+ T cells play a prominent role in protection from
experimental autoimmune encephalomyelitis (EAE) as
depletion of CD8+ T cells from mice that have recovered
from EAE renders them susceptible to the development
of EAE upon reimmunization with myelin basic protein
(MBP). In addition, Cd82/2 PL/J mice develop more
chronic EAE than wild-type PL/J mice. CD8+ T cells
from mice that had recovered from EAE downregulated
or killed some, but not all, CD4+ neuroantigen-specific
T cell clones. Inhibition was blocked by anti-TCR and
anti-CD8, and by antibodies to the MHC class Ib mole-
cule Qa-1, but not by antibodies to MHC class Ia mole-
cules. It has been proposed that Qa-1 self-peptide com-
plexes expressed by activated CD4+ T cells trigger the
TCR on CD8+ T cells. These CD8+ cells then differentiate
into suppressor effector cells that in turn suppress CD4+
T cells expressing the same Qa-1-peptide complex
(Jiang and Chess, 2000). It remains unknown whether
the self-peptides recognized by the CD8+ T cells are
derived from the CD4+ TCR or from activation molecules
induced by antigen-specific stimulation of the antigen-
specific CD4+ T cells. The mechanism of suppression
by these CD8+ T cells is also unknown, although it may
involve differentiation of the CD8+ T cells to cytotoxic
T cells or the secretion of suppressor cytokines. Some
studies suggest that human CD8+ T cells can be induced
to differentiate into regulatory cells whose function is
restricted by HLA-E, the human homolog of Qa-1 (Li
et al., 2001).
CD8+ Treg cells that recognize determinants on immu-
noglobulin molecules have also been detected. Hahn
et al. (2005) used an IgG-VH-region-peptide-based toler-
izing regimen that delays autoantibody production and
nephritis in a murine model of spontaneous lupus-like
disease. Treated mice developed CD8+ T cells that
decreased autoantibody production both in vitro and
in vivo. The action of the induced CD8+ suppressors is
probably on helper CD4+ T cells, because CD8+ T cells
from tolerized mice suppressed IFN-g production in co-
cultures of CD8+ and CD4+ T cells plus B cells, but did
not have direct effects on B cells unless CD4+ T cells
were present in culture. The tolerized CD8+ T cells se-
creted large amounts of TGF-b, and neutralization of
this cytokine abrogated suppression of DNA antibody
production.
The second class of CD8+ Treg cells appears to re-
semble the murine CD4+ Tr1 cells subset because their
suppressive effects are primarily mediated by IL-10. Gil-
liet and Liu (2002) were the first to demonstrate that
stimulation of CD8+ T cells with plasmacytoid DCs re-
sulted in the induction of IL-10-producing CD8+ T cells
that inhibited the proliferative response of naive CD8+
T cells when stimulated with allogeneic monocytes,
immature DCs, or mature DCs. The generation of CD8+
IL-10-producing DCs was also IL-10 dependent.
Wei et al. (2005) have isolated plasmacytoid DCs from
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After CD40L activation and pulsing with tumor-associ-
ated peptide antigen, these plasmacytoid DCs could
induce antigen-specific CD8+CCR7+ IL-10-producing
Treg cells that suppressed the responses of tumor-anti-
gen-specific CD4+ T cells. CD8+CCR7+ IL-10-producing
T cells were found in blood, malignant ascites, and
tumor-draining lymph nodes in patients with ovarian
cancer.
A second population of CD8+ IL-10 producing Treg has
been defined as expressing high amounts of CD122, the
IL-2 receptor b-chain. The percentage of CD122+CD8+
T cells is high (w50%) in young mice, but decreases to
w10% at 7–10 weeks of age, and increases again in older
mice (Rifa’i et al. 2004). Most of the studies have been
done with cells from 6-week-old mice. Cd122-deficient
mice develop an autoimmune syndrome that can be pre-
vented when neonates are injected with CD8+CD122+
T cells. RAG-deficient mice that received CD8+CD1222
cells die from an autoimmune like syndrome within 10
weeks after cell transfer, indicating that CD8+CD1222
cells become activated in the absence of CD8+CD122+
T cells. Interestingly, CD4+CD25+ T cells do not control
the disease induced in RAG-deficient mice by transfer
of CD8+CD1222 cells, and CD8+CD122+ Tregs cells are
Foxp32 and cannot be induced by activation of
CD8+CD1222 T cells in vitro. CD8+CD122+ Tregs inhibit
the activation of both CD8+ and CD4+ T cells in vitro to
plate bound anti-CD3 in the absence of APCs. IL-10
produced by the CD8+CD122+ T cells appears to be the
factor responsible for suppression of proliferation and
IFN-g production. Thus, CD8+CD122+ T cells from IL-
10-deficient mice were incapable of suppressing T cell
activation in vitro, but did show some activity in vivo
in suppressing the activity of wild-type CD8+CD1222 T
cells, suggesting that CD8+CD122+ T cells may use addi-
tional suppressor mechanisms (Endharti et al., 2005).
A distinct type of CD8+ Treg cells develops after re-
peated stimulation of human T cells in vitro with xenoge-
neic APCs or with antigen-pulsed APCs. These CD8+
T cells are CD282 and express Foxp3 mRNA. The most
interesting property of the CD8+CD282 regulatory T cells
is that they target APCs and render them tolerogenic.
Exposure of monocytes and DCs to this subset of regu-
latory T cells results in increased expression of genes
encoding Ig-like transcripts, ILT3 and ILT4, members
of the NK-cell inhibitory-receptor family. Both ILT3 and
ILT4 display long cytoplasmic tails containing immunor-
eceptor tyrosine-based inhibitory motif. Expression of
these receptors is associated with inhibition of NF-kB
activation and with a reduced capacity of the APCs to
transcribe NF-kB-dependent costimulatory molecules.
It has been postulated that antigen-specific MHC class
I restricted CD8+CD282 T regulatory cells first induce
ILT-expressing tolerogenic DCs, which in turn generate
CD4+ regulatory T cells (Vlad et al., 2005).
Is there a CD8+ counterpart of the CD4+CD25+Foxp3+
nTreg? Cosmi et al. (2003) have characterized a popula-
tion of CD8+CD25+ human thymocytes that were
noncytolytic, had reduced expression of perforin and
granzyme A, and mediated suppression by a cell-con-
tact-dependent mechanism that could be reversed by
anti-CLTA-4 or anti-TGF-b. This population, therefore,
in some respects resembles human nTreg although thesuppressive effects of the latter are usually not blocked
by anti-CTLA-4 or anti-TGFb. The expression of Foxp3
by this thymocyte subpopulation was not determined,
and it also unknown whether a similar subpopulation is
present in normal human peripheral lymphoid tissues.
CD4+CD25+Foxp3+ T cells are thought to display an
enhanced affinity for self-MHC class II. Another ap-
proach to search for the CD8+ homolog of the Foxp3+
nTreg is to isolate a population of CD8+ T cells that are
self-MHC class I restricted. Indeed, repeated stimulation
of human CD8+ T cells with LPS-activated DC, followed
by cloning, resulted in the identification of a number of
CD8+ T cell clones that were not anergic, but responded
to stimulation with DCs in an HLA-restricted manner,
produced IL-4 and IL-13, but not IFN-g, and expressed
CTLA-4 and Foxp3 (Jarvis et al., 2005). They suppressed
IFN-g production and proliferation by CD4+ T cells in a
contact-dependent manner that could be reversed by
anti-CTLA-4, but not by anti-cytokine mAb. A similar
population of cells has been described in the rat, where
they suppressed the transfer of graft versus host disease
(Xystrakis et al., 2004). CD8+CD25+Foxp3+ T cells have
also been seen in MHC class II-deficient, but not in
wild-type or MHC class I- and class II- double-deficient
mice (Bienvenu et al., 2005; G. Stephens and E.M.S., un-
published data). These cells are likely to be restricted by
MHC class I molecules and functionally appear to be very
similar to nTreg in their suppressive capacity in vitro.
Double-Negative Treg
CD42CD82 double-negative (DN) Treg cells compose
1%–3% of peripheral T lymphocytes in rodents. DN
Treg cells isolated from mice that have permanently ac-
cepted allo- or xenografts can specifically suppress and
kill syngeneic antidonor CD4+ and CD8+ T cells in vitro.
DN Treg cells, upon expansion in vitro with allogeneic
donor lymphocytes, can specifically suppress prolifera-
tion of syngeneic CD4+ and CD8+ T cells in vitro and pro-
long donor-specific allogeneic-skin-graft survival when
infused into syngeneic naive mice (Chen et al., 2005).
Human DN Treg cells have also been isolated and char-
acterized (Fischer et al., 2005). These cells compose
0.8%–1% of total human peripheral blood CD3+ T cells
and 2.5% of lymph node T cells. Human DN Treg cells
can also suppress immune responses mediated by syn-
geneic CD8+ T cells in an antigen-specific and dose-de-
pendent manner. A rather unique mechanism has been
proposed for the fine specificity of the DN Treg. Both
mouse and human DN Treg cells are cytotoxic to synge-
neic CD8+ T cells that express the same TCR specificity
as the DN Treg cells. DN T cells can acquire via their TCR
allo-MHC peptides from antigen-presenting cells and
use them to specifically trap and kill CD4+ and CD8+ T
cells that recognize the same allo-MHC peptides
through a process that requires cell-cell contact and
Fas-FasL interaction.
In summary, it is difficult to draw solid conclusions
about the biologic significance of any of the CD8+ Treg
or the DN subsets. Do they represent the ‘‘flavor of
the month’’ that never achieves lasting popularity or
do they represent important targets for therapeutic
manipulation?
Concluding Remarks
One of the troubles with having multiple flavors of ice
cream (when I was growing up, the 28 available at
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Three potential pathways by which T regulatory cells can mediate their suppressive effects on a number of different types of target cells including
effector T cells, antigen-presenting cells (APCs), and B cells. Two of the pathways involve direct suppression of the target cells, whereas the
secretion of suppressor cytokines may lead to bystander suppression.Howard Johnson’s, and today, with a few more—31—at
Baskin-Robbins) is that it was always difficult to make
a selection, and in reality, many of flavors were not easily
distinguishable from one another. Selection of the most
important and biologically relevant Treg cell population
is easy. Vanilla remains the most popular flavor of ice
cream in the U.S. today, and there is little doubt that
the critical role of the Foxp3+ nTreg cells in the immune
system is firmly established. The relative importance of
thymic-derived versus peripherally generated Foxp3+
nTreg cells still needs to be established, and major dif-
ferences may exist between species in the usage of
these pathways. One very important issue that remains
unresolved is that no progress has been made in eluci-
dating the biochemical and molecular basis of nTreg-
mediated suppression or firmly defining the target
cell(s). The literature is filled with the term ‘‘contact-me-
diated suppression,’’ yet this conclusion is based on a
negative result, the failure to see suppression across
a semipermeable membrane. So, a soluble molecule
that acts in a concentration-dependent fashion at short
range has never been ruled out. Alternatively, if suppres-
sion is mediated by a cell-surface antigen interacting
with its counter-receptor on another cell, identification
of this receptor-ligand pair would greatly facilitate ma-
nipulation of nTreg function positively for the control of
autoimmune disease, allergy, and graft rejection or neg-
atively for the augmentation of the immune response to
tumors or weak vaccines.
The role of Foxp32 IL-10-producing Treg cells is also
reasonably well established, particularly in the immune
response to pathogens. Yet, the factors that control
the generation of populations of T cells that selectively
produce IL-10 and not Th1- or Th2-type cytokines
in vitro and in vivo need to be much better defined.
The availability of an immunization protocol using an
adjuvant that would facilitate the selective priming of an-
tigen-specific IL-10-only producers would be a majoradvance in the development of a vaccine for organ-spe-
cific autoimmune diseases or for infectious diseases
with a substantial inflammatory component. However,
one aspect of the Tr1 cell subset that has been ignored
by most immunologists is that Tr1 populations frequently
produce small to moderate amounts of other cytokines,
particularly IFN-g. We need to consider the possibility
that such dual producers actually play an important
role in vivo as a type of helper and suppressor cell (or
‘‘hermaphrocyte’’ [Gershon et al., 1976]) whose function
would be regulated by the signals derived from the
microenvironment.
Lastly, it is well worth considering the possibility that
the Treg field need not involve 28 or 31 different subsets
with distinct mechanisms of suppression, but can easily
be explained by three (vanilla, chocolate, strawberry)
suppressive mechanisms that may be used separately
or together (neapolitan) by different cell types: (1) a novel
cell-contact pathway, (2) suppressor cytokines—IL-10,
TGF-b, etc., and (3) killing (Zhao et al., 2006) (Figure 2).
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